Verona Pharma plc (VRNA)
NASDAQ: VRNA · Real-Time Price · USD
83.95
-1.59 (-1.86%)
Jun 6, 2025, 3:11 PM - Market open
Verona Pharma Stock Forecast
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for Verona Pharma stock ranges from a low of $57 to a high of $107. The average analyst price target of $78.8 forecasts a -6.13% decrease in the stock price over the next year.
Price Target: $78.80 (-6.13%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Verona Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 3 | 3 | 3 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $85 → $90 | Strong Buy | Maintains | $85 → $90 | +7.21% | Jun 2, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $93 → $107 | Buy | Maintains | $93 → $107 | +27.46% | Apr 30, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $75 → $85 | Strong Buy | Maintains | $75 → $85 | +1.25% | Apr 30, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $74 → $93 | Buy | Maintains | $74 → $93 | +10.78% | Feb 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $60 → $75 | Strong Buy | Maintains | $60 → $75 | -10.66% | Feb 28, 2025 |
Financial Forecast
Revenue This Year
418.75M
from 42.28M
Increased by 890.44%
Revenue Next Year
744.27M
from 418.75M
Increased by 77.74%
EPS This Year
0.32
from -2.16
EPS Next Year
1.94
from 0.32
Increased by 505.10%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 474.7M | 943.3M | 1.3B | ||
| Avg | 418.8M | 744.3M | 977.5M | ||
| Low | 356.8M | 513.9M | 686.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1,022.8% | 125.3% | 69.8% | ||
| Avg | 890.4% | 77.7% | 31.3% | ||
| Low | 743.9% | 22.7% | -7.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.87 | 4.55 | 4.76 | ||
| Avg | 0.32 | 1.94 | 2.78 | ||
| Low | 0.08 | 0.15 | 0.46 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 1,319.5% | 145.4% | ||
| Avg | - | 505.1% | 43.3% | ||
| Low | - | -54.1% | -76.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.